Lasa Supergenerics Ltd.
Snapshot View

View in App

Prices View details >>

26.25 -0.05 ▼-0.2%

27 January 2023, 04:01:00 PM
Volume: 10,897

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.lasalabs.com
Market Cap 105.34 Cr.
Enterprise Value(EV) 103.52 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) -2.73 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2022-09
Industry PE 32.90 Trailing Twelve Months Ending 2022-09
Book Value / Share 31.95 Trailing Twelve Months Ending 2022-09
Price to Book Value 0.81 Calculated using Price: 25.90
Dividend Yield 0.97 Period Ending 2022-03
No. of Shares Subscribed 4.07 Cr. 40,672,668 Shares
FaceValue 10
Company Profile
The company is specialises in ‘catalyst chemistry' and manufactures anthelmintic/ veterinary API products with the largest production capabilities and product categories in India

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-0.19%
1 Week
+0.38%
1 Month
-20.45%
3 Month
-22.68%
6 Month
-35.90%
1 Year
-62.07%
2 Year
-68.86%
5 Year
-85.54%
10 Year

Ratios View Details >>

7 years 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 8.65 14.33 -10.81 2.94 15.17 -3.49
Return on Capital Employed (%) 14.45 12.80 -3.73 6.77 17.14 -3.54
Return on Assets (%) 2.07 4.79 -4.44 1.50 10.43 -2.64

Balance Sheet View Details >>

Particulars 8 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 0 75 117 105 141 159 149 130
Non Curr. Liab. 0 83 62 43 11 8 7 8
Curr. Liab. 70 107 107 76 41 44 43
Minority Int.
Equity & Liab. 0 228 287 255 229 208 199 181
Non Curr. Assets 149 178 170 153 144 127 137
Curr. Assets 0 79 109 86 76 64 72 44
Misc. Exp. not W/O 0
Total Assets 0 228 287 255 229 208 199 181

Profit Loss View Details >>

Particulars 8 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 199 244 170 167 202 137 129
Other Income 2 3 1 0 0 0 0
Total Income 201 247 170 167 203 137 130
Total Expenditure -153 -202 -159 -137 -155 -121 -128
PBIDT 48 45 12 30 47 16 1
Interest -12 -11 -8 -8 -2 0 -1
Depreciation -8 -18 -19 -17 -16 -14 -13
Taxation 0 -3 4 -1 -7 1 0
Exceptional Items -26 -8 2
PAT 2 12 -12 4 23 -5 -11
Adjusted EPS 472 5 -5 1 6 -1 -3

Cash Flow View Details >>

Particulars 7 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 0 -3 40 41 14 41 10
Cash Fr. Inv. 0 -44 -7 -2 -4 -3
Cash Fr. Finan. 0 0 4 -33 -10 -36 0
Net Change 0 -3 0 0 2 1 7
Cash & Cash Eqvt 0 0 1 0 3 4 11

Shareholding Pattern View Details >>

9 Qtrs 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%)
Promoter 64.47 64.47 64.47 64.47 64.47 45.01 43.78 43.78 43.78
Public 35.53 35.53 35.53 35.53 35.53 54.99 56.22 56.22 56.22
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 43.23 35.15 31.19 31.19

Announcements View Details >>

Fri, 20 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the quarter ended December 31 2022 received from Bigshare Services Private Limited Registrar and Share Transfer Agent of the Company.
Sat, 31 Dec 2022
Closure of Trading Window
This is to inform you that as per the Companys Code of Conduct for Regulating Monitoring and Reporting of Trading by Insiders in terms of (Prohibition of Insider Trading) Regulations 2015 as amended the trading window for dealing in the equity shares of the Company has been closed for designated employees and their immediate relatives w.e.f. January 01 2023 till 48 hours after the declaration of unaudited financial results (both days inclusive) for the quarter ended December 31 2022.
Sat, 24 Dec 2022
Disclosure Under Reg 30 Of SEBI (Listing Obligations And Disclosure Requirements ) Regulations 2015 Regarding Approval Of Scheme Of Amalgamation By Thehon'Ble NCLT
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to Inform you that The Scheme of Amalgamation of Harishree Aromatics and Chemicals Private Limited the Transferor Company with Lasa Supergenerics Limited the Transferee Company is approved by Honble National Company Law Tribunal Mumbai Bench on Friday December 23 2022

Technical Scans View Details >>

Fri, 27 Jan 2023
High Delivery Percentage High Delivery Percentage
Close Within 52 Week Low Zone Close Within 52 Week Low Zone
Close Below Last Month Low Close Below Last Month Low
High Decrease in 1 Month High Decrease in 1 Month
High Decrease in 3 Months High Decrease in 3 Months

Related Stocks View Details >>

  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 249,710.79 1,040.75 +0.1%
Divi's Laboratories Ltd. 89,875.72 3,385.55 +1.5%
Cipla Ltd. 84,895.40 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. 71,960.69 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. 61,265.20 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. 52,047.83 1,537.85 -1.3%
Abbott India Ltd. 45,216.39 21,279.00 0.0%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 60.84 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 30.03 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-12 32.18 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 19.75 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 72.97 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.63 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-09 51.28 21,279.00 0.0%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-09 4.70 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-09 7.41 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-12 3.74 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.27 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.24 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.17 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-09 16.66 21,279.00 0.0%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 0.04 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 0.00 21,279.00 0.0%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 29.95 21,279.00 0.0%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 29.95 21,279.00 0.0%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 4,919.27 21,279.00 0.0%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,040.75 +0.1%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,385.55 +1.5%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,051.80 +1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,321.35 +2.8%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,260.90 +0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,537.85 -1.3%
Abbott India Ltd. Standalone 2022-03 798.70 21,279.00 0.0%

FAQ's On Lasa Supergenerics Ltd.

What is Lasa Supergenerics share price?
Can I buy Lasa Supergenerics shares now?
What is the Dividend Yield of Lasa Supergenerics?
What is the Market Cap of Lasa Supergenerics?
What are the key metrics to analyse Lasa Supergenerics?
What is the 52 Week High and Low of Lasa Supergenerics?
What is the trend of Lasa Supergenerics share price?